Vascular Endothelial Growth Factor (VGEF) Inhibitors Market: 36% Market Growth to Originate from North America | Technavio

NEW YORK, May 17, 2022 /PRNewswire/ -- Technavio categorizes the global vascular endothelial growth factor (VEGF) inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. The vascular endothelial growth factor (VEGF) inhibitors market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Key Drivers, Trends, and Challenges

• The high target affinity and specificity of VEGF inhibitors are driving the growth of the vascular endothelial growth factor (VEGF) inhibitors market.
• The increase in popularity of combination therapies is a vascular endothelial growth factor (VEGF) inhibitors market trend that is expected to have a positive impact in the coming years.
• The preference for gene therapy is expected to be a major challenge for the vascular endothelial growth factor (VEGF) inhibitors market during the forecast period.

View market report outlook to learn more about factors influencing the market.

Vendor Insights

The report identifies the following as the dominant vendors in the market:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• AVEO Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Bristol-Myers Squibb Co.
• Clovis Oncology Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Product Insights and News

The vascular endothelial growth factor (VEGF) inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. For instance, abbvie.com, one of the leading vendors under the operating segment, offers research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.

Learn more about the vendors in the market as you download your sample copy

North America's Contribution to the Vascular Endothelial Growth Factor (VEGF) Inhibitors Market

The sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC, are expected to facilitate the vascular endothelial growth factor (VEGF) inhibitors market growth in North America over the forecast period. 36% of the market's growth will originate from North America during the forecast period as the US and Canada are the key markets for vascular endothelial growth factor (VEGF) inhibitors in North America. Market growth in this region will be slower than the growth of the market in the Asian and ROW regions.

Download report sample right here and know more about the market contribution in APAC

Get your report sample copy to unlock scope and parent market analysis insights

Pandemic Impact

In 2020, the outbreak of COVID-19 adversely affected the US in North America. The outbreak led to radical changes and disturbances in various medical procedures. Moreover, the pandemic negatively impacted the growth of the regional VEGF inhibitors market in 2020 and the first half of 2021 and prompted vendors to develop new business strategies to deal with the impact. Vendors are implementing various strategies such as new product launches, M and A, and collaborations to enhance the growth of the market. 

Key Highlights

• CAGR of the market during the forecast period 2022-2026
• Accurate predictions on upcoming trends and changes in consumer behavior
• Precise estimation of the vascular endothelial growth factor (VEGF) inhibitors market size and its contribution to the parent market
• The growth of the vascular endothelial growth factor (VEGF) inhibitors industry across North America, Europe, Asia, and the Rest of the World (ROW)
• Detailed information on factors that will drive vascular endothelial growth factor (VEGF) inhibitors market growth during the next five years
• A thorough analysis of the market's competitive landscape and detailed information on vendors

Related Reports:

Global Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2022-2026 Download your sample

Topical rugs Market by Product and Geography - Forecast and Analysis 2022-2026 Download your sample

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary ? Chart on Market Overview
• Exhibit 02: Executive Summary ? Data Table on Market Overview
• Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
• Exhibit 04: Executive Summary ? Chart on Market by Geography
• Exhibit 05: Executive Summary ? Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary ? Chart on Incremental Growth
• Exhibit 07: Executive Summary ? Data Table on Incremental Growth
• Exhibit 08: Executive Summary ? Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers ? Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers ? Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants ? Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes ? Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry ? Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Application

• 5.1 Market segments
• Exhibit 24: Chart on Application - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Application - Market share 2021-2026 (%)

• 5.2 Comparison by Application
• Exhibit 26: Chart on Comparison by Application
• Exhibit 27: Data Table on Comparison by Application

• 5.3 Oncology - Market size and forecast 2021-2026
• Exhibit 28: Chart on Oncology - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Oncology - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Oncology - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Oncology - Year-over-year growth 2021-2026 (%)

• 5.4 Opthalmology - Market size and forecast 2021-2026
• Exhibit 32: Chart on Opthalmology - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Opthalmology - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Opthalmology - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Opthalmology - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Application
• Exhibit 36: Market opportunity by Application ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.11 Japan - Market size and forecast 2021-2026
• Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AstraZeneca Plc
• Exhibit 85: AstraZeneca Plc - Overview
• Exhibit 86: AstraZeneca Plc - Key news
• Exhibit 87: AstraZeneca Plc - Key offerings

• 10.4 Bausch Health Companies Inc.
• Exhibit 88: Bausch Health Companies Inc. - Overview
• Exhibit 89: Bausch Health Companies Inc. - Business segments
• Exhibit 90: Bausch Health Companies Inc. - Key offerings
• Exhibit 91: Bausch Health Companies Inc. - Segment focus

• 10.5 Bayer AG
• Exhibit 92: Bayer AG - Overview
• Exhibit 93: Bayer AG - Business segments
• Exhibit 94: Bayer AG - Key news
• Exhibit 95: Bayer AG - Key offerings
• Exhibit 96: Bayer AG - Segment focus

• 10.6 Eisai Co. Ltd.
• Exhibit 97: Eisai Co. Ltd. - Overview
• Exhibit 98: Eisai Co. Ltd. - Business segments
• Exhibit 99: Eisai Co. Ltd. - Key offerings
• Exhibit 100: Eisai Co. Ltd. - Segment focus

• 10.7 F. Hoffmann La Roche Ltd.
• Exhibit 101: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 102: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 103: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 104: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 105: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Novartis AG
• Exhibit 106: Novartis AG - Overview
• Exhibit 107: Novartis AG - Business segments
• Exhibit 108: Novartis AG - Key offerings
• Exhibit 109: Novartis AG - Segment focus

• 10.9 Pfizer Inc.
• Exhibit 110: Pfizer Inc. - Overview
• Exhibit 111: Pfizer Inc. - Business segments
• Exhibit 112: Pfizer Inc. - Key news
• Exhibit 113: Pfizer Inc. - Key offerings
• Exhibit 114: Pfizer Inc. - Segment focus

• 10.10 Regeneron Pharmaceuticals Inc.
• Exhibit 115: Regeneron Pharmaceuticals Inc. - Overview
• Exhibit 116: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibit 117: Regeneron Pharmaceuticals Inc. - Key offerings

• 10.11 Sanofi SA
• Exhibit 118: Sanofi SA - Overview
• Exhibit 119: Sanofi SA - Business segments
• Exhibit 120: Sanofi SA - Key news
• Exhibit 121: Sanofi SA - Key offerings
• Exhibit 122: Sanofi SA - Segment focus

• 10.12 Takeda Pharmaceutical Co. Ltd.
• Exhibit 123: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 124: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 125: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 126: Takeda Pharmaceutical Co. Ltd. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 127: Inclusions checklist
• Exhibit 128: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 129: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 130: Research methodology
• Exhibit 131: Validation techniques employed for market sizing
• Exhibit 132: Information sources

• 11.5 List of abbreviations
• Exhibit 133: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library and its client base consist of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

SOURCE Technavio